Roivant Sciences Valuation
| ROIVWDelisted Stock | USD 2.68 0.36 11.84% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Roivant Sciences holds a recent Real Value of $2.2 per share. The prevailing price of the company is $2.68. Our model determines the value of Roivant Sciences from analyzing the company fundamentals such as Operating Margin of (37.08) %, ebitda of (1.11 B), and Cash And Equivalents of 2 B as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Roivant Sciences' price fluctuation is very steady at this time. Calculation of the real value of Roivant Sciences is based on 3 months time horizon. Increasing Roivant Sciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Roivant stock is determined by what a typical buyer is willing to pay for full or partial control of Roivant Sciences. Since Roivant Sciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Roivant Stock. However, Roivant Sciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.68 | Real 2.2 | Hype 2.68 | Naive 2.56 |
The intrinsic value of Roivant Sciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Roivant Sciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Roivant Sciences helps investors to forecast how Roivant stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Roivant Sciences more accurately as focusing exclusively on Roivant Sciences' fundamentals will not take into account other important factors: Roivant Sciences Total Value Analysis
Roivant Sciences is at this time anticipated to have takeover price of 0 with market capitalization of 0, debt of 481.4 M, and cash on hands of 2 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Roivant Sciences fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
0 | 0 | 481.4 M | 2 B |
Roivant Sciences Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The latest return on assets of Roivant indicates not a very effective usage of assets in November.Roivant Sciences Profitability Analysis
The company reported the revenue of 61.28 M. Net Loss for the year was (1.12 B) with profit before overhead, payroll, taxes, and interest of 0.About Roivant Sciences Valuation
Our relative valuation model uses a comparative analysis of Roivant Sciences. We calculate exposure to Roivant Sciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Roivant Sciences's related companies.Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company was founded in 2014 and is based in London, the United Kingdom. Roivant Sciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 620 people.
Roivant Sciences Growth Indicators
Investing in growth stocks can be very risky. If the company such as Roivant Sciences does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 712.8 M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in Roivant Stock
If you are still planning to invest in Roivant Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Roivant Sciences' history and understand the potential risks before investing.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |